BioAgeDiagnostics published a new article exploring the science, clinical applications, and limitations of pharmacogenetic testing.

BioAgeDiagnostics is a specialised B2B precision longevity platform and distribution partner enabling healthcare providers to deliver integrated, data-driven longevity care. We provide access to advanced biological age and molecular diagnostic platforms — including multi-organ biomarker analytics and epigenetic testing — alongside a curated portfolio of regulated therapeutics, NAD+ formulations, peptides, metabolic injectables, performance compounds, and longevity-focused medical protocols. Precision longevity is built on validated biomarkers, genetic intelligence, and measurable outcomes. Genetics informs predisposition. Epigenetics reveals biological state. Therapeutics enable targeted optimisation. Through integrated diagnostic and therapeutic infrastructure, we move from isolated insights to structured longevity care — from data to intervention. By combining laboratory innovation with clinically governed therapeutic implementation, BioAgeDiagnostics enables providers to operationalise measurable, scalable healthspan optimisation across modern preventive and precision medicine frameworks.